このエントリーをはてなブックマークに追加
ID 47067
本文ファイル
著者
Tsutani, Yasuhiro 原爆放射線医科学研究所 広大研究者総覧
Miyata, Yoshihiro 原爆放射線医科学研究所 広大研究者総覧
Fujitaka, Kazunori 大学院医歯薬保健学研究科(医) 広大研究者総覧
Doi, Mihoko
Awaya, Yoshikazu
Kuyama, Shoichi
Kitaguchi, Soichi
Ueda, Kazuhiro
Hattori, Noboru 大学院医歯薬保健学研究科(医) 広大研究者総覧
Okada, Morihito 原爆放射線医科学研究所 広大研究者総覧
NDC
医学
抄録(英)
[BACKGROUND]:We evaluated the safety and efficacy of induction chemotherapy with bevacizumab followed by maintenance chemotherapy with bevacizumab for advanced non-small cell lung cancer (NSCLC) in this multicenter phase II study.
[METHODS]:Chemotherapy-naïve patient with stage IIIB-IV or recurrent nonsquamous NSCLC were eligible. We planned approximately four cycles of induction cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and bevacizumab (15 mg/kg) followed by maintenance with pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) until disease progression. Progression-free survival (PFS) was the primary endpoint.
[RESULTS]:Forty patients received a median of four induction chemotherapy cycles. Of them, 35 (87.5%) patients received a median of nine maintenance chemotherapy cycles. The objective response was 70.6%, and the disease control rate was 97.1%. The median PFS was 10.8 (95% CI, 9.0-12.6), and overall survival was 48.0 (95% CI, 32.9-63.1) months. Median PFS of 23 patients with epidermal growth factor receptor (EGFR) mutations and of 16 patients without EGFR mutations were 12.9 (95% CI, 9.4-16.3) and 7.9 (95% CI, 1.1-14.7) months, respectively. Toxicities graded ≥3 included neutropenia (15%), anemia (15%), hypertension (7.5%), anorexia (7.5%), fatigue (7.5%), thromboembolic events (5%), jaw osteonecrosis (5%), nausea (2.5%), oral mucositis (2.5%), tumor pain (2.5%), hyponatremia (2.5%), and gastrointestinal perforation (2.5%). Treatment-related deaths were not found.
[CONCLUSIONS]:In patients with advanced or recurrent nonsquamous NSCLC, induction chemotherapy with cisplatin, pemetrexed, and bevacizumab followed by maintenance chemotherapy with pemetrexed and bevacizumab is safe and effective regardless of their EGFR mutation status.
内容記述
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
掲載誌名
BMC Cancer
18巻
開始ページ
1231
出版年月日
2018-12-10
出版者
BioMed Central
ISSN
1471-2407
出版者DOI
PubMedID
言語
英語
NII資源タイプ
学術雑誌論文
広大資料タイプ
学術雑誌論文
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
権利情報
© The Author(s). 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
関連情報URL
部局名
原爆放射線医科学研究所
病院
医歯薬保健学研究科